Oncology corporate
1 – 10 of 37
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Hypogammaglobulinemia at Diagnosis is Associated With Inferior Survival and Higher Risk of Infections in Diffuse Large B Cell Lymphoma
(
- Contribution to journal › Article
-
Mark
Complement Factor H Is an ICOS Ligand Modulating Tregs in the Glioma Microenvironment
(
- Contribution to journal › Article
- 2024
-
Mark
Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy
(
- Contribution to journal › Letter
-
Mark
ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia
(
- Contribution to journal › Article
-
Mark
ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia☆
(
- Contribution to journal › Article
-
Mark
Clinical characteristics and outcomes of 476 mantle cell lymphoma patients aged 80 years and older
(
- Contribution to journal › Letter
-
Mark
Comparing visual inspection with acetic acid, with and without Lugol's Iodine for triage of HPV self-sample positive women in Ethiopia : a randomized controlled trial
(
- Contribution to journal › Article
-
Mark
MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and TP53/p53 – a Nordic Lymphoma Group study
(
- Contribution to journal › Article
-
Mark
Body mass index and risk of over 100 cancer forms and subtypes in 4.1 million individuals in Sweden : the Obesity and Disease Development Sweden (ODDS) pooled cohort study
(
- Contribution to journal › Article
-
Mark
Infections in patients with mantle cell lymphoma
(
- Contribution to journal › Article